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Summary  PRP  is  commonly  used  in  sports  medicine  and  because  it  is  supposed  to  increase
healing capacities  of  damaged  tissues,  it  is  expected  to  be  increase  efﬁciency  or  god  clinical
outcomes  when  added  to  arthroscopic  surgical  procedure.  The  current  review  of  literature
explores the  evidence-based  medicine  supporting  the  use  of  PRP  in  three  arthroscopic  related
disorders. Regarding  cartilage  lesions  of  the  knee,  many  studies  are  exploring  several  aspect  of
cartilage lesion  treatment.  It  appears  that  PRP,  in  some  protocols  with  speciﬁc  concentration,
should be  more  efﬁcient  than  current  therapies  in  the  treatment  of  early  stages  of  knee  OA,
but only  in  the  ﬁeld  of  rheumatology  or  sport  medicine,  not  when  used  during  surgery.  PRP  have
been used  in  ACL  reconstruction,  no  beneﬁt  has  been  reported  in  any  study  regarding  clinical
or radiological  outcomes.  In  shoulder  cuff  disorder,  to  date,  no  clinical  beneﬁt  nor  increased
healing rate  have  been  clearly  reported.  Thus,  in  2013,  it  is  clear  that  there  is  no  evidence  base
medicine data  supporting  the  use  of  PRP  in  arthroscopic  surgery.
Level of  evidence:  2.
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IntroductionPRP  can  currently  be  used  in  addition  to  orthopaedic  surgery.
Focusing  on  arthroscopic  surgery,  we  analyzed  the  litera-
ture  in  order  to  understand  what  is  the  best  practice  we
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an  conclude  from  previous  clinical  studies.  We  thus  focus
n  knee  and  shoulder  disorders.  After  a  short  report  of  PRP
rinciple  of  action,  we  focused  on  its  efﬁciency  in  those
oints  disorders.ationale
he  ﬁrst  element  to  understand  is  what  PRP  is.  Plasma  is  the
erum  including  thrombocytes  (or  platelets),  coagulation
.
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actors  and  proteins.  Platelets  are  cells  containing  many
lements,  have  no  nucleus  but  contain  almost  one  thou-
and  proteins,  acting  as  signals,  located  inside  or  outside
f  the  membrane.  They  also  include  small  granules  (alpha,
elta  and  lambda)  and  especially  50  to  80  alpha  granules  per
latelet  [1].  There  are  several  types  of  alpha  granules  which
omposition  depends  of  the  chronology  of  release  during  the
ealing  process.  In  those  granules  are  located  almost  thirty
ypes  of  proteins  called  growth  factors  (GF)  are  there  are
ostly  involved  in  hemostasis  and  healing  process  [2].
Growth  factors  are  released  from  platelets  through  a
hysiological  activation  by  human  thrombin  after  the  injury
nd  then  are  regularly  renewed  through  a  cascade.
Some  growth  factors  are  also  released  by  other  tissues
ike  fat  tissue  or  liver  or  can  be  found  in  the  blood  inde-
endently  of  platelet  release.  Most  of  GF  have  a  very  short
alf-life.
The  mechanism  is  complex  at  the  time  of  induction  of
issue  repair,  but  also  during  each  step  of  tissue  repair  and
emodeling.  Thus,  their  action  is  mostly  local,  limited  in
ime  and  location.  And  they  have  different  or  even  opposite
ffects  depending  on  other  local  conditions  like  concen-
ration  time  of  release,  tissue  in  concern  or  other  present
roteins  in  media.  Especially,  the  action  of  the  same  GF  is
ifferent  in  cartilage,  bone  or  tendon. .  .  from  catabolism  to
ealing.  .  . Hopefully,  it  is  supposed  that  nature  will  ﬁnd  the
ood  GF  in  the  good  condition  to  repair  organs,  and  that  is
he  rationale  for  PRP  use.
PRP  is  plasma  with  an  amount  of  platelets  largely  above
erum  base  line  (from  3  to  8).  Basically,  the  aim  is  to  increase
he  healing  properties  of  the  organ  by  increasing  the  amount
f  platelets  thus  local  growth  factors.  PRP  is  obtained  using
pinning  kits.  But  volume,  presence  of  blood  cells,  viscos-
ty  (liquid,  matrix)  is  very  different  depending  of  the  kits
n  the  market.  Huge  differences  have  been  found  between
ifferent  systems  of  preparing  in  studies:  some  systems  are
eliable  in  quality  and  volume,  some  are  not.  Doctors  must
e  aware  of  what  they  inject.
A  major  issue  is  to  understand  the  way  to  use  PRP.  It
eems  very  important  that  the  local  increased  concentration
f  GF  keeps  intact  the  physiological  balance  of  GF  in  order  to
espect  interaction  between  GF  and  possibly  reproduce  and
ncrease  the  real  healing  process.  Once  again  it  is  supposed
hat  the  body  will  take  whatever  it  needs  to  heal  correctly.
There  is  a  lot  of  experimental  data  suggesting  that  PRP
hould  be  used  in  clinical  practice,  even  if  the  action  mech-
nisms  are  not  clearly  explained  [3,4].
We  know  PRP  is  efﬁcient  on  cells  (especially  isolated)
n  vitro  and  in  animal  experimental  studies.  But  because
njected  PRP  is  a  cocktail  of  growth  factors,  it  is  hazardous
o  extrapolate  those  fundamental  studies  to  clinical  beneﬁt.
The  aim  of  the  current  review  of  literature  is  to  better
nderstand  what  is  the  evidence  based  medicine  for  the  use
f  PRP  in  shoulder  and  knee  disorders,  independently  from
xperimental  research,  in  order  to  propose  clinical  recom-
endations.
artilage  lesions  of  the  kneehere  is  no  evidence-based  medicine  regarding  the  use  of
RP  in  the  knee  arthroscopy,  but  many  studies  are  reporting
ata  that  start  to  be  useful.
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One  of  the  ﬁrst  studies  of  Sampson  [5]  in  2010,  was
ery  simple:  on  14  patients  complaining  about  knee  OA,  the
uthors  performed  3  injection  of  PRP  every  4  weeks,  inspired
rom  acid  hyaluronic  injections.  Authors  noted  global  clini-
al  beneﬁt  and  pain  decrease  at  1  year  FU.
The  same  year,  Kone  [6]  reports  an  interesting  prospec-
ive  study  focusing  on  rationale  of  PRP  use.  She  considers
hat,  as  far  as  PRP  increases  repair  and  decrease  catabolism
f  cartilage,  and  because  PRP  enhances  chondrocytes
nabolism  and  decrease  synovial  inﬂammation,  there  should
e  a  clinical  beneﬁt.  This  study  involves  80  patients,
15  knees,  and  three  injections  of  5  cc  PRP  every  3  weeks.
ven  if  it  is  the  same  team,  the  protocol  has  change  from
reviously,  and  the  clinical  outcomes  are  still  evaluated  at
 year  FU.  There  is  a  statistically  signiﬁcant  increase  of  IKDC
core,  and  a  decrease  of  pain,  but  the  effect  is  fading  over
ne  year.  Some  important  predicting  factors  are  identiﬁed:
esults  are  worth  in  elderly  patients  and  women.  Beneﬁt  is
ess  important  for  advanced  stages  of  OA  or  high  body  mass
ndex  patients.  An  other  study  from  Wang-Saegusa  [7]  involv-
ng  261  patients  with  a very  close  protocol  (three  injections
very  2  weeks)  and  clinical  results  at  6  months,  reports  sta-
istically  signiﬁcant  beneﬁt  without  any  complication.  Gobbi
8]  reports  clinical  beneﬁt  of  PRP  (two  injections  at  1  month)
n  50  patients,  with  signiﬁcant  beneﬁt  at  1  and  2  years  FU.
It  is  necessary  to  keep  in  mind  that  the  same  data  are
ound  when  focusing  on  hyaluronic  acid.  Thus  it  was  natu-
ally  that  comparative  studies  were  performed.
Elisabetha  Kone  [9]  performed  a  prospective  comparative
evel  2  study  including  150  patients  divided  in  three  groups:
hree  injections  of  PRP  in  group  1,  three  injections  of  low
olecular  weight  hyaluronic  acid  in  group  2,  and  three  injec-
ions  of  high  molecular  weight  hyaluronic  acid  in  group  3.
linical  assessment  was  performed  at  2  and  6  months.  PRP
emonstrates  superiority  to  other  treatment  in  all  scores
sed  in  the  current  study,  and  a  signiﬁcant  improvement  of
ain.  The  same  limitation  factor  was  found,  elderly  patients
id  not  answer  to  treatment.
It  was  also  noted  that  if  no  radiographic  sign  of  OA  is
een.  The  clinical  outcomes  are  better  with  PRP  at  6  months.
he  more  the  OA  is  advanced,  the  worst  the  clinical  ben-
ﬁt  is  shown.  At  the  beginning  radiographic  stage  of  OA,
RP  are  still  efﬁcient  but  with  lower  difference  compare  to
ther  treatment.  For  advance  radiographic  stage  of  OA,  no
reatment  is  efﬁcient.
A  double  blind  prospective  randomized  level  1  study
nvolved  109  patients  treated  by  PRP  vs.  hyaluronic  acid
10]. Three  injections  where  performed  in  each  group.  No
tatistically  signiﬁcant  difference  was  found  in  any  element
f  clinical  outcomes  at  6  months  except  for  some  patients
ho  had  higher  local  pain  after  PRP  injection.  In  the  cur-
ent  study  it  is  interesting  to  point  out  some  elements:  the
latelet  concentration  is  very  high,  ﬁve  times  the  natural
oncentration,  and  a  high  concentration  of  leucocytes  is
njected,  that  are  subject  to  discussion  in  literature  and
harged  to  induce  pain.  At  least,  patients  are  older  than
n  other  study,  and  it  has  been  demonstrated  how  it  can
adly  affect  clinical  outcomes.  In  the  current  study,  PRP  is
tored  in  cold  before  injection,  element  that  can  modulate
fﬁciency  of  the  platelets.
Another  double  blind  prospective  randomized  level  1
tudy  [11]  involved  176  patients  with  a  mean  age  of  60  years,
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mostly  women.  Thirty-eight  percent  of  patient  treated  by
PRP  had  an  increase  of  50%  of  their  WOMAC  functional  score
compared  to  24%  of  patient  treated  by  hyaluronic  acid  with
a  increase  of  50%  of  their  functional  score.  The  difference
was  statistically  signiﬁcant.  No  side-effect  was  notiﬁed  in
any  group.
Another  equivalent  study  demonstrated  that  the  effect
observed  with  PRP  vs.  hyaluronic  acid,  is  still  persistent  at
2  years  FU  [12].  This  tendency  is  always  present,  whatever
the  stage  of  OA  is,  even  if  efﬁciency  is  clearly  better  for
early  stages  of  knee  OA.
ACL  reconstruction
In  a  prospective  randomized  level  one  study,  Nin  [13]
assessed  the  beneﬁt  of  PRP  during  allograft  ACL  recon-
struction  in  two  populations  of  50  patients.  Clinical  and  MRI
assessment  was  performed,  and  no  statistically  signiﬁcant
difference  was  seen.
In  a  prospective  level  3  study,  25  patients  had  an  ACL
reconstruction  without  PRP,  and  25  with  PRP.  Technical  pro-
cedure  was  not  always  the  same,  and  reconstruction  was
performed  whether  with  bone  tendon  bone  or  hamstring  lig-
aments  graft.  The  only  difference  was  noted  in  MRI  signal
of  the  reconstruction  that  seems  more  homogeneous  in  PRP
group  [14].
In  two  level  one  studies,  it  was  signiﬁcantly  demonstrated
that  the  use  of  PRP  decreases  pain  of  donor  site  after  bone
tendon  bone  harvesting  [15,16].  PRP  does  not  act  on  graft
ﬁxation  at  the  bone  tendon  junction  or  does  not  inﬂuence
the  size  modiﬁcations  of  tunnels  [17,18].
Shoulder  cuff  repair
Chahal  [19]  recently  performed  a  meta-analyze  of  ﬁve  stud-
ies,  two  randomized,  three  not  randomized,  exploring  the
effect  of  PRP  on  cuff  repair.
The  ﬁrst  one  is  a  prospective  randomized  level  one  study,
comparing  clinical  outcomes  when  using  or  not  PRP  as  a
matrix.  Small  to  moderate  lesions  were  repaired  with  double
row  procedure,  and  Constant  score  and  MRI  were  performed
20  months  after  surgery  [20].
No  difference  was  seen  in  any  group  regarding  clinical
result  and  imaging.  Authors  notiﬁed  one  failure  of  repair  in
PRP  group  vs.  4  in  control  group,  but  no  statistically  sig-
niﬁcant  difference  was  seen,  probably  also  related  to  low
number  of  patients.
Randelli  [21]  did  compare  two  groups  with  or  other  with-
out  PRP  injection  during  repair.  Clinical  outcomes  and  MRI
were  performed  at  24  months.  At  3  months  all  scores  are  bet-
ter  in  PRP  group,  but  with  time,  no  difference  continue.  Just
like  in  the  previous  study,  MRI  demonstrated  higher  failure
in  control  group,  without  clinical  difference.
The  study  of  Barber  [22],  a  level  3  study,  including  two
groups  of  20  patients,  found  a  beneﬁt  of  PRP  in  clinical  out-
come.  MRI  found  also  a  higher  re-tear  rate  in  control  group
with  a  statistically  signiﬁcant  difference.
Jo  [23]  study  didn’t  ﬁnd  any  statistically  signiﬁcant  dif-
ference  between  two  groups  of  patient  operated  of  a  cuff
repair  with  or  without  PRP  injection.  One  more  time  itS409
ppears  a  lower  re-tear  occurrence  in  PRP  group,  without
tatistically  signiﬁcant  difference.
Bergeson  [24]  analyzed  the  effect  of  RPR  on  challenging
uff  repair,  including  patient  exposed  to  rotator  cuff  repair
ailure  (aged,  fatty  inﬁltration).  One  more  time,  indepen-
ently  of  clinical  outcomes,  it  appears  that  PRP  statistically
ncreases  the  healing  rate.  Authors  report  two  cases  over  16
f  local  infection,  which  is  subject  to  caution.
In  these  ﬁve  studies,  follow  up  is  between  19  to
1  months,  260  patients  are  included  with  a  mean  age  of
9  years  old.  No  statistically  signiﬁcant  difference  is  seen
egarding  complications  or  clinical  outcomes.  There  is  less
e-tear  in  the  PRP  group,  it  is  signiﬁcant  for  medium  to  small
ears,  it  is  just  a  tendency  for  massive  tears.
One  level  one  study  including  large  tears  reports  no  re-
ear  in  PRP  group,  with  statistically  signiﬁcant  difference,
ut  without  correlation  with  clinical  scores  [25].
Last  study  is  from  Rodeo  and  is  a  prospective  randomized
evel  2  study,  using  a Doppler  US  to  assess  vascularization  and
ealing.  If  scores  and  vascularization  are  the  same,  there  is
 higher  re-tear  rate  in  PRP  group  [26].
onclusion
f  use  of  PRP  is  technically  easy,  we  have  to  keep  in  mind
hat  it  is  a  changing  cocktail  of  growth  factors,  acting  just
fter  injection,  and  poorly  mimicking  healing  process.
It  is  reasonable  to  say  that  in  knee  disorders,  PRP  seems
o  be  efﬁcient  to  treat  early  stages  of  knee  OA,  this  effect
hould  be  prolonged  up  to  one  year,  and  is  superior  to
yaluronic  acid  injection.  But  it  is  clear  that  exact  modal-
ties  of  injection  are  still  unclear,  and  probably  exploring
his  therapy  is  more  devoted  to  rheumatology  practice.
egarding  shoulder  and  cuff  repair,  if  it  seems  that  the
ealing  rate  is  increased,  we  have  enough  evidence-based
edicine  to  say  that  there  is  no  clinical  beneﬁt  to  use  PRP
n  2013.  At  least,  it  is  clear  that  there  is  no  evidence  base
edicine  data  supporting  the  use  of  PRP  in  arthroscopic
urgery.
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